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Abstract
Plasmodium vivax infection has been gaining attention because of its re-emergence in several parts of the world.
Southeastern Turkey is one of the places in which persistent focal malaria caused exclusively by P. vivax parasites occurs.
Although control and elimination studies have been underway for many years, no detailed study has been conducted to
understand the mechanisms underlying the ineffective control of malaria in this region. Here, for the first time, using
serologic markers we try to extract as much information as possible in this region to get a glimpse of P. vivax transmission.
We conducted a sero-immunological study, evaluating antibody responses of individuals living in Sanliurfa to four different
P. vivax antigens; three blood-stage antigens (PvMSP119, PvAMA1-ecto, and PvSERA4) and one pre-erythrocytic stage
antigen (PvCSP). The results suggest that a prior history of malaria infection and age can be determining factors for the
levels and sustainability of naturally acquired antibodies. Significantly higher antibody responses to all the studied antigens
were observed in blood smear-negative individuals with a prior history of malaria infection. Moreover, these individuals
were significantly older than blood smear-negative individuals with no prior history of infection. These data from an area of
sole P. vivax-endemic region may have important implications for the global malaria control/elimination programs and
vaccine design.
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Introduction
Plasmodium vivax parasites are the main cause of widespread
human malaria infections, with at least 35–80 million cases
reported each year [1,2]. Although neglected for a long time, the
morbidity and public health burden caused by P. vivax is very high,
resulting in renewed attention [3,4,5]. There is a general
consensus that acquired immunity to P. vivax is age-dependent
and develops more quickly than immunity to P. falciparum
[5,6,7,8]. However, P. vivax parasites have distinct biological
features, such as persistence in the host due to hypnozoites/
relapses, effective gametocyte production, and rapid and efficient
adaptation to mosquitoes [9]. Therefore, several questions remain
to be addressed before an effective vaccine can be developed:
What are the antigen(s) eliciting protective immune responses?
What are the immunological correlates for protection (e.g. serum
immunoglobulins such as P. vivax-specific IgG and IgM, cytokines
and chemokines)? What are the host age groups? What are the
kinetics of acquired immunity against P. vivax? [4]. To date,
analysis of P. vivax infection has been hampered by the fact that the
majority of studies analyzing serological parameters and disease
severity have been performed in patients co-infected with P.
falciparum [6,7,10,11,12,13,14].
Southeastern Turkey is one of the few regions in which P. vivax
is the only Plasmodium species present [15,16,17]. Despite extensive
control measures, an increasing number of malaria cases have
been recorded since the early 1990s. We recently undertook a
sero-epidemiological investigation to understand the endemicity
and host immune responses to P. vivax in Sanliurfa province [16].
In an earlier study, we observed increased sero-reactivity (,54%
IgG positivity) to the C-terminal region of the PvMSP119 antigen
(one of the leading candidate vaccine antigens) in serum samples
from infected individuals [16], and a further study showed limited
and unique pvmsp1 polymorphisms in the parasite population in
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28126Turkey [17]. Therefore, comprehensive studies are needed to
completely understand the immune responses to P. vivax antigens
in this region. Such an understanding will facilitate the design of
effective vaccination strategies against P. vivax [9].
As a first step, in the present study, we analyzed naturally
acquired antibody responses to four P. vivax antigens that may be
potential vaccine candidates. Total IgM and IgG antibody
responses (including IgG subclasses) to three blood-stage antigens,
PvMSP119, PvAMA1-ecto and PvSERA4, and one pre-erythro-
cytic stage antigen, PvCSP, were examined in individuals living in
Sanliurfa. Any association between antibody responses to each of
the P. vivax antigens and the degree of parasitemia in the patients
was investigated. Baseline data provides important information for
the elimination programs targeting vivax malaria by drugs or
vaccines.
Results
Naturally acquired antibody responses to pre-
erythrocytic and erythrocytic antigens
Although the vivax malaria elimination program was launched
in 1925 [18], there is no clear information regarding the
endemicity rates and transmission dynamics in southeastern
Turkey. According to the WHO, P. vivax transmission was
reported in seven Turkish provinces in 2006, and 84% of cases
occurred in the southeastern cities of Diyarbakir and Sanliurfa
[17]. The Sanliurfa region, which accounts for the majority of
malaria cases, has recently been studied [16,17]. For the present
study, 195 serum samples were collected from the towns of Siverek
and Harran.
The naturally acquired immune responses to the four P. vivax
candidate vaccine antigens (PvMSP119, PvAMA1-ecto and
PvSERA4 and PvCSP) were examined and total IgM and IgG
antibody responses (including IgG subclasses) were measured. In
the total study population (n=195), 79.1% individuals were
seropositive for either IgG or IgM against at least one of the four
antigens studied, while 62.1% were seropositive for IgG alone, and
65.6% were seropositive for IgM alone (Table 1). IgG responses to
PvMSP119 were seen most frequently in 50.3% of individuals,
followed by responses to PvCSP (33.8%), PvAMA1-ecto (21%) and
PvSERA4 (16.4%). However, IgM antibody responses to
PvSERA4 and PvCSP were observed in the majority of individuals
(49.2% and 36.9%, respectively) (Table 1). The IgG subclasses
observed in the IgG responders were mainly IgG1, followed by
IgG3. The IgG3 responses to PvCSP were more prevalent than
those to PvSERA4. In addition, IgG2 and IgG4 responses to
PvSERA4 were seen more frequently (in 15.6% and 12.5% of
patients, respectively) than to the other antigens (Table 1). Taken
together, these results show . 60% IgG seroprevalence to tested P.
vivax antigens in individuals living in the Sanliurfa region.
Interestingly, despite the acknowledged lack of sensitivity in
estimating malaria transmission using IgM responses [19], at the
present data-set 35–50% of the samples showed IgM responses to
at least one of the antigens (particularly to PvCSP and PvSERA4).
Antibody responses in relation to a prior history of
malaria infection
Although 2000–6000 cases of malaria were recorded annually
in Sanliurfa up until 2003, the incidence declined rapidly after the
government’s efforts to control the disease using chloroquine and
primaquine [17]. According to the Annual Report of the Sanliurfa
National Malaria Control Center, the incidence of parasite
infection in 2002, 2004 and 2008 was 12.96, 3.20 and 1.85 per
1000 population, respectively [17], and the number of P. vivax
cases decreased by about 86% from 2002 to 2008 and by 42%
from 2004 to 2008. Based on this information that the infection
rate had decreased dramatically over the last decade, we examined
whether there may be any difference in the antibody responses
between younger (, 6 years old) and older individuals. The study
population was grouped according to their history of malaria
infection (Figure 1a). The results showed that 10% of PP (parasite
positive) individuals had a history of malaria infection, but this rose
to 30.5% in PN (parasite negative) individuals (x
2=11.195;
P=0.001). Importantly, the mean age of PN individuals with a
history of malaria infection was significantly higher than that of
individuals with no prior history of infection (27.6617.9 years vs.
16.7614.9 years; P=0.001, t=-3.383). Thus, these observations
suggest that in this region, it appears that repeated exposure to
malaria correlates with significantly higher percentage of PN
individuals.
We next analyzed the naturally acquired antibody responses to
the four candidate antigens according to each individual’s
infection history. Primary P. vivax infections evoked high IgG
responses to all four antigens, both in terms of frequency and
serum concentration in the PP group with no history of malaria
infection (Figure 1b and 1c). In cases of re-infection (which
occurred in 10% of the PP group; Figure 1a), neither the
prevalence nor the level of the IgG responses to the four antigens
changed (Figure 1b and 1c). It is, however, noteworthy that IgG
antibody levels to PvSERA4 were either very low or undetectable
after re-infection. In contrast, PN individuals with a history of
malaria infection showed higher IgG responses to all four antigens
both in terms of frequency and serum levels (*P,0.05 and
**P,0.01; Figure 1b and 1c). However, there was a substantial
IgG response, but a very low response to PvMSP119 and PvCSP in
those PN individuals with no prior history of malaria infection.
Table 1. Anti-P. vivax antibody prevalence in Sanliurfa.
Antigen
Antibody responses (n=195)
Number (%) IgG subclasses among IgG responders (%)
IgG IgM IgG+IgM IgG1 IgG2 IgG3 IgG4
PvMSP1 98 (50.3%) 55 (28.2%) 105 (53.6%) 93.9 11.2 70.4 5.1
PvAMA1-ecto 41 (21.0%) 35 (17.9%) 66 (33.7%) 95 7.5 77.5 7.5
PvSERA4 32 (16.4%) 96 (49.2%) 106 (54.1%) 90.6 15.6 59.4 12.5
PvCSP (chimeric) 66 (33.8%) 72 (36.9%) 88 (45%) 76.9 6.2 86.2 16.9
Total 121 (62.1%) 128 (65.6%) 155 (79.1%)
doi:10.1371/journal.pone.0028126.t001
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relationship of previous malaria exposure and seroconversion to
malaria antigens tested.
Correlation between antibody frequency, serum
concentration and age
We next examined the relationship between age and serum
antibody responses, either between different age groups (Figure 2)
or within the whole study population (Figure 3). With the
exception of PvCSP, the frequency of IgG antibody responses to
most of the antigens tended to increase with age (Figure 2a), while
the serum levels did not differ significantly between the age groups
(Figure 2c). Approximately 10–35% of individuals showed positive
IgG antibody responses to at least one of the antigens by the age of
6, increasing to ,25–60% after the age of 30 (Figure 2a). For the
whole study population, the trend of increasing total IgG responses
with age was most marked for PvSERA4 (r=0.322; P=0.0001)
(Figure 3). IgG3 responses to PvSERA4 and PvAMA1-ecto also
increased significantly with age (r=0.200, P=0.005 and r=0.282,
P=0.0001, respectively; Figure 3).
In contrast, there was no correlation between IgG responses to
any of the antigens and age in the PP population (n=80; data not
shown and Figure 2b). The increase in the IgG response was very
rapid, even in the 0–6 age group, the exception being the IgG
response to PvSERA4 (Figure 2b and Figure 2d). As expected, IgG
responses (both in terms of frequency and serum levels) were lower
in the PN population (n=115; Figure 2b and Figure 2d;
#P,0.05
and
##P,0.01; x
2 test). However, despite the fact that IgG
antibody responses were lower when compared with those in the
whole study population or those in PP individuals (Figure 2d), 72%
of PN individuals showed positive antibody responses (IgG and/or
IgM) to at least one of the antigens (data not shown). Overall, IgG
seropositivity against all the antigens studied (except PvCSP) in the
PN population tended to increase with age (Figure 2b). The
significant increase in the IgG response to PvSERA4 and the IgG3
response to PvAMA1-ecto with age (Figure 3) suggests that
repeated exposure may be required to produce (and sustain) an
increase in IgG responses to these two antigens. The IgG responses
to most of the antigens (except PvSERA4) are apparent at a very
early age; by contrast, IgG responses to PvSERA4 do not develop
quickly after infection (s), but increases with age in concordance
with PN status.
Correlation between antibody levels and parasitemia
We next evaluated the correlation between antibody responses
and parasitemia during patent infection. Total IgG and IgG1
responses to PvCSP were positively correlated with parasitemia
(r=0.245, P=0.029 and r=0.246, P=0.028, respectively;
Figure 1. Impact of malaria infection history on naturally acquired antibody responses against P. vivax antigens. (a) Malaria infection
history (MH) and its relationship to age. The total population was categorized according to blood smear positive (PP) and negative (PN) status for P.
vivax, and then according to malaria infection history and age. The frequency (percentage seropositivity) (b) and serum antibody levels (ROU) (c) of
the total IgG responses against the four antigens are depicted. The x
2 test was used to compare the frequencies and mean ages between groups (a).
Bars (c) represent the mean6SEM, and ROU levels were compared using multiple comparison analysis in conjunction with ANOVA (*P,0.05 and
**P,0.01).
doi:10.1371/journal.pone.0028126.g001
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negatively correlated with parasitemia (r=20.233, P=0.038,
Figure 4). There was no correlation between parasitemia and IgG3
levels for any antigen. These data support that PvCSP responses
correlate well with parasite levels during acute infection [20];
however, the negative correlation between parasitemia and
PvAMA1-ecto IgG responses may suggest an important role for
high antibody levels to AMA1 in controlling parasitemia during
P. vivax infection.
Discussion
Understanding immunity to malaria parasites is crucial for
successful interventions. Despite the introduction of extensive
malaria elimination programs since the 1920s [18], P. vivax malaria
has re-emerged in southeastern Turkey. To date, no study has
been performed to understand the epidemiology and transmission
dynamics of the P. vivax parasites in this region. Southeastern
Turkey is unusual in that individuals are infected with P. vivax
alone, with no co-infection by other malarial species. Thus,
analysis of this region has clear implications for P. vivax biology and
developing various control strategies such as vaccines. Serological
parameters were shown in P. falciparum infections to offer an
advantage for measuring endemicity and malaria transmission
dynamics, because of overcoming sampling variations and the
detection of persistent antibodies over months and years after
infection [21]. We used a similar approach to get an overview/
rapid assessment of P. vivax transmission intensity. Likewise, this
study is the first to analyze a range of serological parameters for
individuals living in Sanliurfa, southeastern Turkey. Evaluations
based on parasite prevalence, parasite exposure history and age
may not be directly correlated with malaria protection but raise
important clues for assessment in this unique malaria setting for P.
vivax eventual monitoring and control.
The results of this study showed that IgG antibody responses to
both pre-erythrocytic and erythrocytic antigens were closely
related to a previous history of malaria infection. While only
10% of the actively infected population had a previous history of
malaria infection, this increased three times (30.5%) in the PN
population. This may indicate that one or two infections may
induce naturally acquired immunity. Supporting this notion, IgG
responses against P. vivax were positively correlated with age.
Figure 2. IgG antibody frequencies and levels according to age groups. IgG antibody frequencies in the total study population (n=195) (a),
and in the blood smear positive (PP; n=80) and blood smear negative (PN; n=115) populations (b). The number of individuals within each age group
is shown in Table 1. # indicates significant differences between the PP and PN as assessed using the x
2 test (#P,0.05, and ##P,0.01). Total IgG
antibody responses (ROU) to the four antigens grouped according to age for the total population (n=195) (c), blood smear positive (PP; n=80) and
negative (PN; n=115) individuals (d). x indicates significant differences in antibody levels (ROU) between blood smear positive and negative groups
using multiple comparison analysis in conjunction with ANOVA (x, P,0.05). * indicates a significant correlation between increases in antibody
frequencies, levels and age (r=0.322, P=0.0001 and r=0.413, P=0.001 in (a, c) and (b, d) respectively).
doi:10.1371/journal.pone.0028126.g002
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which might have implications for future vaccine design. In
addition, the PvAMA1 ectodomain portion may be a potential
candidate vaccine antigen for reducing parasite levels. Whether
these observations can robustly correlate with malaria protection,
a future study should be able to address these using defined
cohorts.
In agreement with previously published studies of P. vivax and P.
falciparum infection, IgG responses to PvMSP119 increased rapidly
during the early ages of infection and were sustained over a long
period of time [21,22,23,24], although there was no significant
correlation between age, parasite levels, and antibody responses to
PvMSP119. However, in an earlier pilot study, we observed higher
sero-reactivity (53.6% IgG responses to PvMSP119) to the C-
terminal region of the PvMSP1 antigen (produced in Saccharomyces
cerevisiae) in the PP population, which was negatively correlated
with parasite levels [16]. In the current study, we did not find any
correlation between antibody responses to PvMSP119 and parasite
number, suggesting the possibility of allelic polymorphisms in the
antigen/parasites. In fact, in a recent study, we did find eight
substitutions in the PvMSP1 gene that were unique to the Turkish
P. vivax population and one of them (D/E at 1706 in the C-
terminal 19-kDa region) was previously unidentified [17]. To
understand whether this unique D/E substitution has impact on
the antibody responses and parasite levels, we measured total IgG
levels in a limited numbers of infected serum bearing the D/E
substitution. Preliminary results suggested that there was an
inverse correlation between anti-PvMSP119 IgG levels and
parasite numbers in individuals infected with E haplotype
substitutions, but not D haplotype substitutions (data not shown,
unpublished observation). It is also noteworthy that other studies from
Brazil and Papua New Guinea reported that different individuals
Figure 3. Correlation between age and total IgG, IgG1 and IgG3 antibody responses (ROU) to P. vivax MSP119, PvAMA1-ecto,
PvSERA4 and chimeric PvCSP antigens in all individuals (n=195). Correlations were evaluated using Spearman’s correlation test.
Significantly correlated values were marked on the each figure (*).
doi:10.1371/journal.pone.0028126.g003
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PvMSP1 [25,26]. Further confirmatory tests would be needed to
substantiate further the effect of different haplotypes/allelic
polymorphisms to antibody responses.
Similar to anti-PvMSP119 responses, antibody levels to chimeric
PvCSP antigen immediately increased in younger individuals, but
the response was weaker than that for PvMSP119, even during
patent infection (Figure 2c). However, these responses did not
completely disappear, and were even sustained in PN individuals
with no evidence of prior malaria infection (presumably naı ¨ve;
Figure 1c). One possible explanation for this might be an ongoing
undetectable level of transmission by mosquitoes in this population
as reported recently, suggesting the occurrence of P. vivax infection
with ultra low-level parasitemia, which may maintain transmission
levels, even under controlled-radical therapy [27]. Although we
were technically unable to confirm the microscopically P. vivax-
negative individuals by PCR in the present dataset, based on our
experience from this region, genus-specific Real-Time PCR could
only detect 4.5% parasite positivity over microscopy even in the
malaria-suspected symptomatic patients (Yuksel and Zeyrek,
unpublished observations). Therefore, it seems unlikely that more than
4.5% of malaria history negative PN group (presumably naı ¨ve)
individuals have undetectable level of parasitemia. We cannot
exclude, however, another possibility of P. vivax infections causing
relapses due to the presence of hypnozoites, even in the absence of
mosquito bites, because of ineffective drug treatment [28,29]. To
date, it has always been a technical difficulty to address how
hypnozoites/ relapses could influence serological profiles [30].
Currently there is no molecular tool to discriminate re-infection
versus relapse during P. vivax infection and this certainly limits
Figure 4. Correlation between parasite density and antibody levels. Total IgG, IgG1 and IgG3 antibody responses (ROU) to P .vivax MSP119,
PvAMA1-ecto, PvSERA4 and chimeric PvCSP antigens were measured in individuals with patent P vivax infection (n=80). Correlations were evaluated
using Spearman’s correlation test. Significantly correlated values are marked on each figure (*).
doi:10.1371/journal.pone.0028126.g004
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probabilities may exceed 20% per year [31]. All together, these
possibilities may explain the higher IgG seropositivity in parasite
and presumably malaria history negative individuals.
We observed antibody responses to PvAMA1-ecto antigens in
this region, although low in frequency and accompanied by low
serum antibody levels. Children infected at a younger age (,6
years old) developed rapid antibody responses to AMA1-ecto
antigen, but these responses were not seen after 6 years of age.
However, the current study provides important evidence that IgG
antibody responses to PvAMA1-ecto domain are significantly
increased in non-infected individuals with a prior history of
malaria infection. In addition, the IgG levels to PvAMA1-ecto
were negatively correlated with parasite levels, which collectively
may suggest that antibodies to PvAMA1-ecto are important and
maybe closely related to protection [32]. These observations
certainly require additional defined-cohort studies to address
antibody levels-protection correlations.
This is the first report analyzing anti-P. vivax SERA4 responses.
The serine repeat antigen (SERA) is an abundant asexual blood-
stage antigen primarily expressed by Plasmodium parasites during
late trophozoite and schizont stages [33,34,35]. In the case of P.
falciparum, upon schizont rupture theabundant Pf SERA gene
family member, SERA5, is processed to yield a 47 kDa N-
terminal, a 50 kDa central, an 18 kDa C terminal, and a 6 kDa
domain [34,35]. The N-terminal 47-kDa domain of P. falciparum
serine repeat antigen 5 (PfSERA5) has already been exploited as a
potential candidate vaccine [34]. An epidemiological study in a
malaria hyper-endemic area of Uganda revealed that naturally-
induced IgG responses to the N-terminal 47 kDa domain were
positively correlated with increased levels of protective immunity
in adults [36]. In earlier studies with P. vivax, the highest
transcription of PvSERA4 in all field isolates [33] parallels that
of PfSERA5. This was our basis on the selection of the expressed
region of PvSERA4, which was similar in amino acid sequence to
the 47-kDa domain of PfSERA5. In this study, we observed IgM
responses to PvSERA4 in 50% of individuals, while only 16%
showed IgG responses. Given that higher IgG levels were more
frequent in the PN population only after re-exposure to malaria
and after certain ages, there is a possibility that seroconversion
from IgM antibodies to IgG for anti-PvSERA4 antibodies, are
somehow not occurring properly. This is an interesting hypothesis
that needs further investigation. Similar to the limited PvMSP119
gene polymorphisms observed in this region [17], initial analysis of
the PvSERA4 gene in Sanliurfa isolates also revealed limited
polymorphisms at the N-terminal region when compared with
parasite isolates from southeast Asia (Arisue N and Horii T,
unpublished observations). However, the polymorphic nature of the
recombinant PvSERA4 antigen used in the present study (and the
other antigens to a similar extent) may also be one reason that we
detected low IgG antibody responses in this region. This, too,
requires further investigation.
This study constitutes a first seroepidemiological analysis/survey
of antibodies to a variety of blood and pre-erythrocytic stage
malarial antigens and provides valuable information in their
relation to the age of the individuals living in a sole P. vivax
endemic region. However, we are far from the conclusion that
naturally acquired antibodies to these relatively small numbers of
vivax proteins could establish malaria immunity and/or protec-
tion. Apparently, new tools such as protein microarrays which
represent at least 20% of the parasite proteome are needed to
evaluate naturally acquired antibodies which may be associated
with naturally acquired vivax malaria immunity in this setting as
similar to recently described study for falciparum malaria [37].
Nevertheless, our study offers valuable insights to those
designing vaccines/drugs especially in the settings where elimina-
tion programs have been launched [38].
Materials and Methods
Ethics Statement
All samples were collected after written informed consent was
obtained from the patients (or the parents of individuals under 18
years of age), prior to anti-malarial treatment when appropriate.
All clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki. Authorization
was obtained from the Turkish Ministry of Health, Sanliurfa
Bureau, and ethical approval was obtained from the Research
Institute for Microbial Diseases, Osaka University.
Study population and demographic characteristics
One hundred and ninety-five serum samples were collected
from individuals in Sanliurfa province (the towns of Siverek and
Harran) in southeastern Turkey during 2004 and 2008. The
samples were collected at the peak of the malaria season (July to
November) and kept at 220uC until use. All 69 serum samples
collected in 2004 were found to be infected with patent P. vivax
malaria (as diagnosed by microscopy) [16]. The unbiased, age and
gender matched 126 serum samples from 2008 were collected
during active surveillance (house-to-house screening) (Table S1).
Of these serum samples, 11 (8.7%) were confirmed P. vivax-
infected using thick blood smears after Giemsa staining. The level
of parasitemia (asexual parasites/mL blood) was determined as
previously described [15]. Statistical analysis showed no significant
difference between the two patient groups in terms of population
demographics and antibody responses (n=69 from 2004 and
n=11 from 2008) (data not shown); and hence, the two sets of
samples were grouped together as ‘‘microscopically positive for P.
vivax parasites’’ (n=80) (see Table S1).
The mean age of the sample population was 20.5616.2 years
[0–77 years] (mean 6 SD [range]), and 47.7% of the subjects were
male. The samples were divided into four age groups: 0–6 years
old (19.5%), 7–15 years old (26.7%), 16–30 years old (33.3%), and
.31 years old (20.5%). Table S1 shows the baseline characteristics
of the study subjects. The study included individuals infected with
P. vivax (P. vivax-positive (PP) according to blood smear results;
n=80) and individuals living in the malaria-endemic area but not
infected with P. vivax at the time of sampling (P. vivax negative (PN)
according to blood smear results; n=115). The mean (mean 6 SD
[range]) age of the two groups was 21.1616 [0–65] years and
20.4616.5 [0–77] years, respectively, and 56.2% and 41.7% of the
respective groups were male. There was a significant difference in
body temperature between the PP and PN groups (37.960.522uC
vs. 36.760.513uC, respectively; P,0.0001). The mean parasite
density was 550266386 [160–25560] parasites/mL. The majority
of the patients (46.3%) had parasite densities between 1001 and
5000 parasites/mL, whereas only 32.5% of the patients had heavy
parasitemia (. 5000 parasites/mL) and 21.3% had very low
parasitemia (, 1000 parasites/mL). Mean hemoglobin, hematocrit
concentrations, and mean white blood cell counts did not vary
significantly between the PP and PN groups (Table S1).
Determination of malaria infection history
Disclosure of malaria infection is compulsory in Turkey and
intervention is controlled by the Turkish Ministry of Health,
alongside local national malaria control centers, in accordance
with the World Health Organization criteria for malaria diagnosis
and treatment. Questionnaires filled out by the subjects or their
Plasmodium vivax Transmission Dynamics in Turkey
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treated for malaria at any of the local malaria control centers. The
answers were cross-checked against the records from the malaria
control centers. The results showed that those individuals with a
history of previous malaria infection had only a single exposure
(. 95%).
Recombinant P. vivax antigens
PvMSP119, PvAMA1-ecto, and PvCSP were expressed using a
wheat germ cell-free protein translation system (CellFree Sciences,
Matsuyama, Japan) [39], whereas PvSERA4 was cloned and
expressed in E. coli as a histidine tagged fusion protein. The PvCSP
was designed as recombinant chimeric protein that presumably
cover vivax parasite population globally as previously described in
detail [40]. PvAMA1-ecto encompasses ectodomain of PvAMA1
(Glu77 to Gln484 based on the SalI sequence, PVX_ 092275). Both
gene fragments were cloned into pEU-E01-His-TEV-N2 plasmid
for the wheat germ cell-free system (CellFree Sciences).
PvSERA4 gene sequence corresponding to amino acid regions
Val19 to Lys352 was amplified from gDNA of SalI after comparing
sequences with NICA and Chesson. The N-terminal position and
prediction of peptide cleavage site was determined using SignalP
3.0 [41]. The C-terminal position was determined by alignment
with PfSERA5 N-terminal domain. After alignment and intron
identification/localization, introns were spliced by overlapping
PCR. The amplified fragment was ligated to pET-15b, and the
resulting plasmid with hexa-His-tag was transformed to E. coli
Rosetta-gami B (DE3) pLysS (Novagen, San Diego, CA). Protein
expression was induced by the addition of isopropyl-b-D-
thiogalactopyranoside to a final concentration of 0.5 mM. The
recombinant protein was extracted into soluble fraction with
BugBuster Master Mix (Novagen) and purified using a His
GraviTrap (GE Healthcare). All antigens were stored at 280uC
until assayed.
Measurement of serum antibody levels by ELISA
The levels of human IgG, IgM, IgG1, IgG2, IgG3, and IgG4
antibodies against PvMSP119, PvCSP, PvAMA1-ecto and
PvSERA4 were measured by ELISA as previously described
[42,43]. Briefly, 96-well microtiter plates (Maxisorb, Nunc,
Denmark) were coated with either 0.5 or 1 mg/ml of each of the
recombinant antigens in bicarbonate buffer and incubated
overnight at 4uC. After blocking, serum samples (100 ml, diluted
1:100 in a PBS-Tween buffer containing 5% skim milk) were
added to the wells. The serum dilution and the amount of coated
antigen were confirmed in pilot experiments as optimal for the
accurate measurement of antibody levels. After washing four
times, the plates were incubated with horseradish peroxidase-
conjugated secondary antibodies to human IgG, IgM and the four
IgG subclasses (1:1000; Zymed, Carlsbad, USA) at room
temperature for 2 h. The plates were washed four times and 3,
39, 5-59-tetramethylbenzidine (Sigma) was added to each well and
incubated in the dark at room temperature. The optical density
was then measured at 450 nm. Each sample was assayed in
duplicate and each plate contained ‘‘blank’’ wells and control sera.
The OD values were normalized according to cut-off value and
expressed as relative OD units (ROU). Cut-off values were set at
three standard deviations above the mean OD450 measured using
sera from 20 Japanese blood donors with no history of malaria
exposure. After subtracting the cut-off values, any ROU
measurements higher than 0.01 were considered positive. The
cut-off values were as follows: anti-PvMSP119-IgG, IgM, IgG1,
IgG2, IgG3 and IgG4: 0.094, 0.345, 0.052, 0.324, 0.022 and
0.367, respectively; anti-PvAMA1-ecto-IgG, IgM, IgG1, IgG2,
IgG3 and IgG4: 0.145, 0.542, 0.204, 0.32, 0.064 and 0.059,
respectively; anti-PvSERA4-IgG, IgM, IgG1, IgG2, IgG3 and
IgG4: 0.03, 0.405, 0.019, 0.062, 0.0418 and 0.01, respectively; and
anti-PvCSP-IgG, IgM, IgG1, IgG2, IgG3 and IgG4: 0.141, 0.775,
0.14, 0.41, 0.05 and 0.1, respectively.
Statistical analysis
Data from 2004 and 2008 were pooled and/or divided into two
groups: blood smear-positive and blood smear-negative for P.
vivax. The antibody levels in all age groups, and in the blood
smear-positive and -negative groups, were compared using the X
2
test. Differences in antibody levels (expressed as ROU) between
the groups were analyzed using multiple comparison tests in
conjunction with ANOVA. Spearman’s rank correlation was used
to evaluate correlations between the variables. A P value , 0.05
was considered significant. All statistical analysis was performed
using the SPSS statistical package (version 10.0; SPSS, Chicago,
IL, USA).
Supporting Information
Table S1 Demographic characteristics of the study
population. * Significant values were determined between
microscopically confirmed parasite positive vs. parasite negative
populations by Student’s t-test and X
2- tests with a level of
significance set at P,0.05.
a Statistically significant by Student’s
t-test.
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